Compare Gold Fields Limited (GFI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Mesoblast Limited — how do they compare? Gold Fields Limited trades at $41.57 (market cap $36.07B), while Mesoblast Limited trades at $16.98 (market cap $2.21B). The key difference: Gold Fields Limited is far larger — about 16.3× Mesoblast Limited's market cap, and Gold Fields Limited pays a 5.76% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| GFI | MESO | |
|---|---|---|
Market Cap | $36.07B | $2.21B |
Sector | Basic Materials | Technology |
52-Week High | $61.52 | $20.96 |
52-Week Low | $29.31 | $12.88 |
Enterprise Value | $37.51B | $2.21B |
Dividend Yield | 5.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields Limited (GFI) trades at $41.12, up 0.73% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 40.76% net income margin and ROE of 52.33%, though recent quarterly earnings missed expectations. Revenue grew to $5.2B in 2024, with net income reaching $1.25B. Analyst consensus is a Buy with a $52 price target, indicating 26% upside potential.
The outlook for GFI is positive given its robust fundamentals and gold price tailwinds, but risks include volatile earnings performance and rising debt levels. Institutional accumulation and favorable sector sentiment support the bullish case, though investors should monitor cost pressures and execution on growth targets.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
